Coordonnateur: Eric Salvat
Co-coordonnateur: Guy Mensah-Nyagan
General scopes and previous achievements:
Chronic pain is a major health concern. It is a disease per se, but it can also be a comorbidity of other diseases (for example: in schizophrenia and Parkinson’s disease) and it can lead to secondary pathologies (for example: mood disorders, cognitive deficits and sleep disorders). Elucidation of the mechanisms involved in chronic pain and/or related comorbidities, in which genetic predispositions are critical, as well as the development of new effective treatments are major translational challenges. Thanks to various experimentally well-designed preclinical and clinical studies, the associated team members are comparing the mechanisms of action of novel or patented compounds to those evoked by pain drugs currently available in order to develop innovative and effective therapeutic strategies against pain diseases, including nerve tissue injury-induced pain, persistent inflammatory pain or chemotherapy- induced peripheral neuropathic pain. Moreover, the associated teams are studying the genetic controls of pain, the anxio-depressive, cognitive and sleep comorbidities of pain, from molecular and cellular approaches to imaging of pain processes.
Future projects in NEUROGENYCS:
This WP will collaborate with many actors of the FHU by way of the following projects:
1) PHRC “Schizophrenia & pain”,
2) PHRC “Beta2 agonists in pain”,
3) Role of opioid receptors in pain treatments,
4) API “Minocycline in neuropathic pain: neuro-immune targets”,
5) Projects: “Genetic aspects of pain”
6) « Allopregnanolone-based therapy to prevent chemotherapy-induced neuropathy ».